RANI (Rani Therapeutics Holdings) Moat Score: 4/10 (As of Jun. 28, 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.74
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Moat Score?

Rani Therapeutics Holdings RANI -0.58% 32 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,402 Biotechnology companies, Rani Therapeutics Holdings ranks better than 88.8% on this metric.

Rani Therapeutics Holdings has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Rani Therapeutics Holdings has Narrow Moat: Rani Therapeutics Holdings Inc has valuable intellectual property in drug delivery technology. While it faces competition, its patents provide a modest moat, though it lacks strong brand strength or significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Rani Therapeutics Holdings might have Narrow Moat - Discernible but modest moat.

Rani Therapeutics Holdings  (NAS:RANI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Rani Therapeutics Holdings Moat Score Related Terms

RANI vs CGTX, INO, ALDX: Moat Score Comparison

For the Biotechnology subindustry, Rani Therapeutics Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rani Therapeutics Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's Moat Score falls into.


RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Rani Therapeutics Holdings (RANI) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Rani Therapeutics Holdings ranks #157 out of 1402 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Rani Therapeutics Holdings' Moat Score too high?
Rani Therapeutics Holdings' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Rani Therapeutics Holdings' value of 4 is 100% above this industry median. Based on the distribution chart, Rani Therapeutics Holdings ranks #157 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Moat Score compare to CGTX and INO?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #157 out of 1402 companies for Moat Score. This places Rani Therapeutics Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Rani Therapeutics Holdings' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rani Therapeutics Holdings's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price